2011 News

Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
12/28/11
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia. Enobia is a private biopharmaceutical company based in Montreal, Canada and Cambridge, Massachusetts, which is focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disordersmore...
New Data Confirm Hemolysis as Predictor of Thromboembolism and Early Death in Patients with PNH and Demonstrate Need To Test High-Risk Patients for PNH
12/12/11
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of new data that underscore the severity of paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder. PNH is characterized by chronic, uncontrolled complement activation leading to hemolysis (red blood cell destruction), which is measured by the presence of higher than normal levels of lactate dehydrogenase (LDH) throughmore...
Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
11/29/11
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). Soliris is the first therapy approved in the European Union for the treatment of aHUS, an ultra-rare, life-threatening, chronic, genetic disease that progressively damages vitalmore...
Alexion to Present at the 23rd Annual Piper Jaffray Health Care Conference
11/23/11
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the 23rd Annual Piper Jaffray Health Care Conference in New York City at 11:30 a.m. Eastern on Wednesday, November 30, 2011. An audio webcast of Dr. Bell’s remarks will be available live. You can access the webcast at: www.alexionpharma.com. An archivedmore...
Longer-Term Data on Soliris Showed Significant and Sustained Benefits for Patients with aHUS
11/10/11
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today presented longer-term data from the extensions of two pivotal phase 2 studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS): (i) a study in patients with a long duration of disease prior to receiving intervention with Soliris following chronic plasma exchange/infusion (PE/PI) and (ii) a study in patients with a shorter duration of disease prior tomore...
Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting
11/7/11
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data on Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation, at the 53rd Annual Meeting of the American Society of Hematology (ASH).more...
Alexion Reports Third Quarter 2011 Results
10/20/11
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the three and nine months ended September 30, 2011. Third Quarter 2011 Financial Results: For the three months ended September 30, 2011, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported total revenues of $204.0 million from net product sales of Soliris® (eculizumab), compared to $141.6 million in Q3more...
Alexion Pharmaceuticals to Report Third Quarter 2011 Results on Thursday, October 20, 2011
10/6/11
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2011 on Thursday, October 20, 2011 before the financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio web cast on Thursday, October 20, 2011, at 10:00 a.m. Eastern Time (ET). Tomore...
Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
9/23/11
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) for the treatment of all pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). aHUS is an ultra-rare, life-threatening, genetic disease that progressively damages vital organs, leading to stroke, heart attack, kidney failure and death.1 The morbidity and premature mortality in aHUS is caused bymore...
Alexion Receives CHMP Positive Opinion for Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European Union
9/23/11
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe. Based on the CHMP's positive recommendation, a final decision from the Europeanmore...

Alexion Pharmaceuticals

Newsroom Search

Media Contacts

2011 News